Gamco Investors INC. ET AL maintained its position in Meridian Bioscience Inc. (NASDAQ:VIVO) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 175,000 shares of the company’s stock at the end of the second quarter. Gamco Investors INC. ET AL owned 0.42% of Meridian Bioscience worth $2,756,000 at the end of the most recent quarter.
Other institutional investors also recently added to or reduced their stakes in the company. Legal & General Group Plc raised its position in Meridian Bioscience by 9.1% in the second quarter. Legal & General Group Plc now owns 80,546 shares of the company’s stock valued at $1,269,000 after buying an additional 6,738 shares during the period. Bank of New York Mellon Corp raised its position in Meridian Bioscience by 1.1% in the second quarter. Bank of New York Mellon Corp now owns 863,183 shares of the company’s stock valued at $13,595,000 after buying an additional 9,713 shares during the period. SG Americas Securities LLC bought a new position in Meridian Bioscience during the second quarter valued at approximately $238,000. Mondrian Investment Partners LTD raised its position in Meridian Bioscience by 18.6% in the second quarter. Mondrian Investment Partners LTD now owns 177,739 shares of the company’s stock valued at $2,799,000 after buying an additional 27,848 shares during the period. Finally, Arizona State Retirement System raised its position in Meridian Bioscience by 0.5% in the second quarter. Arizona State Retirement System now owns 22,041 shares of the company’s stock valued at $347,000 after buying an additional 100 shares during the period. 86.50% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Meridian Bioscience Inc. (VIVO) opened at 13.75 on Friday. The firm’s 50-day moving average price is $14.33 and its 200 day moving average price is $14.04. The stock has a market capitalization of $580.29 million, a P/E ratio of 27.50 and a beta of 0.89. Meridian Bioscience Inc. has a 12-month low of $10.75 and a 12-month high of $19.85.
Meridian Bioscience (NASDAQ:VIVO) last announced its quarterly earnings results on Thursday, July 27th. The company reported $0.16 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.16. The company had revenue of $50.14 million during the quarter, compared to the consensus estimate of $49.13 million. Meridian Bioscience had a net margin of 10.77% and a return on equity of 16.93%. The company’s revenue for the quarter was down 1.0% compared to the same quarter last year. During the same period in the prior year, the business earned $0.21 earnings per share. Analysts predict that Meridian Bioscience Inc. will post $0.67 EPS for the current fiscal year.
The business also recently declared a quarterly dividend, which was paid on Thursday, August 17th. Stockholders of record on Monday, August 7th were issued a dividend of $0.125 per share. The ex-dividend date of this dividend was Thursday, August 3rd. This represents a $0.50 annualized dividend and a dividend yield of 3.64%. Meridian Bioscience’s dividend payout ratio (DPR) is presently 98.04%.
TRADEMARK VIOLATION NOTICE: “Gamco Investors INC. ET AL Continues to Hold Stake in Meridian Bioscience Inc. (VIVO)” was first published by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of United States & international trademark & copyright laws. The original version of this piece can be accessed at https://stocknewstimes.com/2017/08/26/gamco-investors-inc-et-al-continues-to-hold-stake-in-meridian-bioscience-inc-vivo.html.
Several research firms recently commented on VIVO. BidaskClub lowered Meridian Bioscience from a “sell” rating to a “strong sell” rating in a research report on Wednesday, August 2nd. Zacks Investment Research lowered Meridian Bioscience from a “hold” rating to a “sell” rating in a research report on Thursday, July 13th. Finally, Canaccord Genuity boosted their price target on Meridian Bioscience from $13.00 to $15.00 and gave the stock a “hold” rating in a research report on Wednesday, May 3rd. Three research analysts have rated the stock with a sell rating and four have issued a hold rating to the company. Meridian Bioscience currently has an average rating of “Hold” and a consensus target price of $14.75.
In related news, Chairman John A. Kraeutler purchased 7,000 shares of the stock in a transaction dated Thursday, August 24th. The stock was bought at an average cost of $13.67 per share, for a total transaction of $95,690.00. Following the completion of the acquisition, the chairman now owns 345,230 shares of the company’s stock, valued at $4,719,294.10. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 2.30% of the stock is currently owned by corporate insiders.
About Meridian Bioscience
Meridian Bioscience, Inc is a life science company engaged in the development, manufacture, sale and distribution of diagnostic test kits for gastrointestinal, viral, respiratory and parasitic infectious diseases, and elevated blood lead levels, and the manufacture and distribution of bulk antigens, antibodies, polymerase chain reaction (PCR)/quantitative PCR (qPCR) reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers.
Receive News & Ratings for Meridian Bioscience Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Meridian Bioscience Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
